



PREDICT > TO PREVENT



About PreMD Inc.

PreMD, a leader in predictive medicine, is advancing the health and wellness of people around the world with non-invasive, painless tests for the detection and monitoring of life-threatening diseases, particularly cardiovascular disease (CVD) and cancer. PreMD's unique tests enable the stratification of patients who may be at risk of serious disease, allowing for earlier, more targeted treatment and potentially significant savings to the health care system.

All of PreMD's tests are simple to administer and do not require fasting, dietary changes or patient preparation.

Investment Strengths

- ◁ **Partnered with AstraZeneca Pharmaceuticals in July 2007 for the US marketing and distribution of PREVU* Skin Sterol Test**
 - > Shared vision of cardiovascular disease management
 - > Favorable royalty beginning at 20% on sales
 - > Approximately \$6.0 million in milestone payments
- ◁ **Multiple predictive products developed to meet recognized medical needs in high-potential global markets**
 - > Broadens revenue opportunities while reducing risk
 - > Lead cardiovascular product cleared for sale in the U.S., Canada and Europe
 - > Strong clinical validation for all products
- ◁ **Effective, low-risk business model**
 - > Focused on already-proven technologies that can be developed into products quickly
 - > Clinical trials largely funded by third parties, enabling a low cost structure
- ◁ **Strategic relationships with world-leading organizations**
- ◁ **Poised to generate revenue**

Recent News

AUGUST 23, 2007 – New breast cancer clinical data accepted for presentation at San Antonio Breast Cancer Symposium

AUGUST 14, 2007 – PASA abstract to be presented at American Heart Association Conference

AUGUST 14, 2007 – PreMD announces second quarter results

JULY 16, 2007 – PreMD signs marketing and distribution agreement with AstraZeneca Pharmaceuticals

JUNE 19, 2007 – American Stock Exchange accepts PreMD's continued listing plan

Financial Highlights

Exchanges:

TSX: PMD

Amex: PME

Shares Outstanding:

23 million

Recent Price:

TSX: CDN\$1.78

Amex: US\$1.73

52-week High/Low:

TSX: CDN\$3.35 – \$0.89

Amex: US\$3.00 – \$0.94

Market Capitalization:

TSX: CDN\$45 million

Amex: US\$42 million

Cash Position:

\$3.5 - \$4 million

Insider Ownership:

Approx. 20%

Contact Information

Head Office

4211 Yonge Street, Suite 615

Toronto, Ontario M2P 2A9

www.premdinc.com

IR Contact

Michelle Rabba

Manager, Corporate

Communications

T: 416-222-3449 ext. 25

mrabba@premdinc.com



Market Potential

- > CVD claims the lives of 17 million people worldwide each year (WORLD HEALTH ORGANIZATION, ATLAS OF HEART DISEASE AND STROKE, 2004)
- > Every 26 seconds one American will suffer a coronary event, and about every minute, someone will die from one (AMERICAN HEART ASSOCIATION, HEART DISEASE AND STROKE STATISTICS, 2005 UPDATE)
- > Colorectal, lung and breast cancers combined kill approximately two million people annually worldwide (WORLD HEALTH ORGANIZATION/INTERNATIONAL ASSOCIATION FOR CANCER RESEARCH, GLOBOCAN 2000: CANCER INCIDENCE, MORTALITY AND PREVALENCE WORLDWIDE)
- > Only 39% of colorectal cancers, 16% of lung cancers and 63% of breast cancers are found at an early, localized stage (AMERICAN CANCER SOCIETY, CANCER FACTS AND FIGURES, 2006)

Products

CARDIOVASCULAR

PreMD's predictive test for cardiovascular disease measures the amount of cholesterol, or sterol, in the skin tissues. Skin sterol correlates to the presence and extent of coronary artery disease, and to prior heart attack.

- > PREVU* Point of Care Skin (POC) Sterol Test, a three-minute professional test that has been cleared for sale in the U.S. (CLIA exempt), Canada and Europe. PREVU* POC is available for sale to medical professionals in North America and select European markets;
- > PREVU* LT Skin Sterol Test, a lab-processed test currently in clinical trials, designed for use in the life insurance testing industry; and
- > PREVU* PT Skin Sterol Test, a home test currently in development.

CANCER

PreMD's cancer tests (in development) detect early-stage disease by identifying a cancer-associated sugar in a sample of rectal mucus, sputum or nipple aspirate.

- > ColorectAlert™, a minimally invasive screening test for early-stage colorectal cancer, detects more early-stage cancer than fecal occult blood tests (FOBT);
- > LungAlert™, a non-invasive screening test for early-stage lung cancer, has been shown to detect more than half of early-stage cancers; and
- > A breast cancer detection test.



PREVU* PT Skin Sterol Test



PREVU* POC Skin Sterol Test



LungAlert™

Management Team

Brent Norton, MD, MBA, President & CEO; Mike Evelegh, PhD, Executive Vice President, Regulatory & Clinical Affairs; Ron Hosking, CA, Vice President & CFO; and Tim Currie, Vice President, Corporate Development

Board of Directors

Stephen A. Wilgar, MBA (CHAIRMAN); Anthony F. Griffiths, MBA; Ron Henriksen, MBA; Brent Norton, MD, MBA; and David Rosenkrantz, P.Eng.

Scientific Advisory Board

John Bienenstock, MD, McMaster University; Herbert A. Fritsche, Jr., PhD, M.D. Anderson Cancer Center; Norman Marcon, MD, University of Toronto; and Dennis L. Sprecher, MD, GlaxoSmithKline.